Journal
ACS MEDICINAL CHEMISTRY LETTERS
Volume 3, Issue 1, Pages 58-62Publisher
AMER CHEMICAL SOC
DOI: 10.1021/ml200230e
Keywords
Alzheimer's disease (AD); neurofibrillary tangles (NFTs); imaging benzothiazole; PET
Categories
Funding
- NEXT
- Ministry of Education, Culture, Sports, Science and Technology, Japan
- Grants-in-Aid for Scientific Research [23650182] Funding Source: KAKEN
Ask authors/readers for more resources
We synthesized and evaluated (E)-4-((6-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)benzo[d]thiazol-2-yl)diazenyl)-N,N-dimethylaniline (FPPDB) as a probe for the imaging of neurofibrillary tangles (NFTs) in patients with Alzheimer's disease (AD). In assays using thioflavin S (ThS) as a competitive ligand, FPPDB competed with ThS well and showed high affinity for both tau and A beta(1-42) aggregates (K-i = 13.0 and 20.0 nM, respectively). The results of saturation binding assays also verified that FPPDB bound to both tau and A beta(1-42) aggregates with high affinity (K-d = 44.8 nM and B-max = 45.8 pmol/nmol protein for tau aggregates and K-d = 45.4 nM and B-max = 38.9 pmol/nmol protein for A beta(1-42) aggregates). Furthermore, [F-18]FPPDB substantially labeled NFTs and senile plaques in AD brain sections but not control brain sections. In biodistribution experiments using normal mice, [F-18]FPPDB displayed higher uptake (4.28% ID/g at 2 min postinjection) into and washout (2.53% ID/g at 60 min postinjection) from the brain with time. On the basis of the chemical structure of FPPDB, further increases in selective binding to tau aggregates may lead to the development of more useful probes for the imaging of NFTs in AD brains.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available